October 14, 2019 Clinical Research/Diagn. Life Science Tools Product Launch

PerkinElmer Launches PG-Seq™ Rapid Non-Invasive Preimplantation Genetic Testing Kit as Alternative to IVF Embryo Biopsies

New kit shown to achieve over 90% correlation rate between biopsied embryos and testing spent culture media WALTHAM, Mass. – October 14, 2019 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today introduced its PG-Seq™ Rapid Non-Invasive Preimplantation Genetic Testing for Aneuploidy (PGT-A) kit. This solution tests spent embryo culture... Read more

October 10, 2019 Cell Analysis Tools Clinical Research/Diagn. M&A, Partnerships

MilliporeSigma Becomes the First to Use Acoustic Technology for Cell Therapy Manufacturing

MilliporeSigma today announced it has acquired FloDesign Sonics, of Wilbraham, Massachusetts, developer of a unique acoustic cell processing platform 10 OCT 2019 | BURLINGTON, MASSACHUSETTS, UNITED STATES OF AMERICA Acquisition of FloDesign Sonics marks next step in autologous manufacturing  MilliporeSigma today announced it has acquired FloDesign Sonics, of Wilbraham, Massachusetts,  developer of a unique acoustic cell processing platform for... Read more

October 10, 2019 Clinical Research/Diagn. Microscopy PR/Corporate

GE Healthcare Selected as Vendor of Choice for NYC Health + Hospitals $224 Million Investment to Upgrade Medical Imaging Technology System-Wide

230 medical imaging units will be replaced and updated within first four years Equipment will support the public health system’s goal of standardizing care and providing patients modernized, state-of-the-art imaging technology New York, NY – October 10, 2019 –NYC Health + Hospitals today announced that it is investing $224 million over ten-years to upgrade medical imaging technology... Read more

October 9, 2019 Clinical Research/Diagn. Licensing, IP, and Legal M&A, Partnerships

GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer

Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment. The two companies will leverage their combined scientific, commercial and market access expertise to work towards a commercial launch. Chalfont St Giles, UK – October 9th 2019 – GE Healthcare and Theragnostics have entered into a global commercial partnership for a... Read more

October 7, 2019 Clinical Research/Diagn. Environ, Ag./Food & Bev Life Science Tools M&A, Partnerships

QIAGEN and Illumina Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

San Diego, California, Hilden, Germany and Germantown, Maryland – October 7, 2019 – Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management. The agreement grants QIAGEN non-exclusive... Read more

October 2, 2019 Chromatography Clinical Research/Diagn. Lab Top-10 PR/Corporate

Agilent Receives Approval for First PD-L1 Companion Diagnostic in China

Agilent Receives Approval for First PD-L1 Companion Diagnostic in China SANTA CLARA, Calif., October 2, 2019 Agilent Technologies Inc. (NYSE: A) today announced that the National Medical Products Administration (NMPA, formerly the China Food and Drug Administration) has approved its PD-L1 IHC 22C3 pharmDx assay for use in China. The assay is now approved as... Read more

September 30, 2019 Atomic Spectroscopy Clinical Research/Diagn.

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 30 September 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares... Read more

September 27, 2019 Clinical Research/Diagn.

Strategic Change in Development of Oncolytic Virus Immunotherapy C-REV

This article is translated from press release in Japanese for your convenience. Forward-Looking Statements Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management... Read more

September 24, 2019 Clinical Research/Diagn. Mass Spectrometry Product Launch

Fluidigm Becomes the First Company to Enable 50-Plex Cytometry Panels with the Release of Seven New Metal Antibody Labels

Powering industry-leading CyTOF technology to deliver new insights in translational and clinical research SOUTH SAN FRANCISCO, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has launched seven new cadmium metal labeling kits for use with mass cytometry. The newly available... Read more

September 24, 2019 Clinical Research/Diagn.

GE Healthcare expands oncology PET tracer portfolio – aims to improve patient response rates to immunotherapies

Partnering with multiple companies to develop targeted PET imaging tracers to better predict and monitor individual patient response to immunotherapies PET tracers would help increase patient response rates which currently average between 20-40% Initially PET tracers would support pharma companies to enhance clinical trials enabling speed-to-market for immunotherapies Chalfont St Giles, UK –September 24 2019... Read more